The use of basiliximab in solid organ transplantation

REFERENCES

• SOMMER BG, HENRY ML, FERGUSON RIVI: Sequential antilymphoblast globulin and cyclosporine for renal transplantation. Transplantation (1987) 43:85–90.
   PubMedGoogle Scholar
• DIETHELM AG, DEIERHOI MH, HUDSON SL et al.: Progress in renal transplantation: a single center study of 3359 patients over 25 years. Ann. Surg. (1995) 221:446–458.
   PubMedGoogle Scholar
• TAKEMOTO S: Sensitization and crossmatch. In Clinical Transplants. Cecka JM, Terasaki PI (Eds) UCLA Tissue Typing Laboratory. Los Angeles, CA, USA (1996):417–424.
   Google Scholar
• BENVENISTY AL, COHEN D, STEGALL MD, HARDY MA: Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function. Transplantation (1990) 49:321–327.
   PubMedGoogle Scholar
• ABRAMOWICZ D, NORMAN DJ, VEREERSTRAETEN P: OKT3 prophylaxis in renal grafts with prolonged ischemia times: associated with improvement in long-term survival. Kidney mt. (1996) 49:768–772.
   PubMedGoogle Scholar
• KOHAUT EC, TEJANI A: The 1994 annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr. Nephrol. (1996) 10:422–434.
   PubMed Web of Science ®Google Scholar
• AMLOT PL: The clinical and experimental use of monoclonal antibodies to the IL-2 recptors. In Monoclonal Antibodies in Transplantation. Chatenoud 1 (Ed.). R.G. Landes, Austin, TX, USA (1995):53–98.
   Google Scholar
• QUEEN C, SCHNEIDER WP, SELICK HE: A humanized antibody that binds to the interleukin 2 receptor. Proc. Nati Acad. Sci. USA (1989) 86:10029–10033.
   PubMed Web of Science ®Google Scholar
• AMLOT PL, RAWLINGS R, FERNANDO ON et al.: Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation (1995) 60:748–756.
   PubMed Web of Science ®Google Scholar
• NASHAN B, MOORE R, SCHMIDT A-G et al.: Randomized trail of Basiliximab versus placepo for control of acute cellular rejection in renal allograft recipients. Lancet (1997) 350:1193–1198.
   PubMed Web of Science ®Google Scholar
• KAHAN BD, RAJAGOPALAN PR, HALL M: Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2- receptor monoclonal antibody. Transplantation (1999) 67:276–284.
   PubMed Web of Science ®Google Scholar
• MULLOYLL, WRIGHT F, HALL ML, MOORE M: Basiliximab (simulect) reduces acute cellular rejaction in renal allograft from cadaveric and living donors. Transplant. Proc. (1999) 31:1210–1213.
   PubMedGoogle Scholar
• THISTLETHWAITE JR Jr, NASHAN B, HALL M et al.: Reduced acute rejection and superior 1-year renal allograft survival with Basiliximab in patients with diabetes mellitus. The Global Basiliximab Study Group. Transplantation (2000) 70(5):784–790.
   Google Scholar
• PONTICELLI C, YUSSIM A, CAMBI V et al.: A randomized, double-blind trial of Basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation (2001) 72:1261–1267.
   PubMed Web of Science ®Google Scholar
• HENRY ML, PELLETIER RP, ELKHAMMAS EA et al.: A single center experience with Basiliximab induction therapy in renal transplantation. Transplant. Proc. (2001) 33:3178–3179.
   PubMedGoogle Scholar
• SOLLINGER H, KAPLAN B, PESCOVITZ MD et al.: Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation (2001) 72:1915–1919.
   PubMed Web of Science ®Google Scholar
• LEBRANCHU Y, BRIDOUX F, BUCHLER M et al.: Immunoprophylaxis with Basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am. .1 Transplant. (2002) 2:48–56.
   Google Scholar
• TSAI MK, CHU SH, HU RH et al.: Renal transplantation with Basiliximab (simulect) plus Sandimmune Neoral-based immunosuppression: a report of 41 cases in Taiwan. Transplant. Proc. (2001) 33:3194.
   PubMedGoogle Scholar
• KANDUS A, KOVAC D, BUTUROVIC-PONIKVAR J et al.: Absence of acute rejection using Basiliximab with triple immunosuppression in cadaveric kidney recipients in first three months. Transplant. Proc. (2001) 33:3207–3208.
   PubMedGoogle Scholar
• HARTLE JE, BISORDI JE, CHO S et al:The addition of Basiliximab to cellcept, neural and steroid resulted in a significant reduction in acute renal allograft rejection. Transplantation (2000) 69:S159.
   Google Scholar
• FOLKMANE I, BICANS J, AMERIKA D et al.: Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with Basiliximab. Transplant. Proc. (2001) 33:3209–3210.
   PubMed Web of Science ®Google Scholar
• PHILOSOPHE B, FINK JC, WILAND AM et al.: Low kidney rejection rates with Basiliximab induction and delayed introduction of tacrolimus for patients with delayed graft function. Transplantation (2000) 69:S259.
   Google Scholar
• BRENNAN DC, The Thymoblobulin induction study group: A prospective, randomized, multi-center study of Thymoglobulin compared to Simulect for induction immunosuppression: preliminary results. American Transplant Congress Chicago, IL, USA (2002): Abstract 398.
   Google Scholar
• WEIMAR W, VAN RIEMSDIJK IC, SMAK GREGOOR PJH et al: Anti-CD25 prophylaxis allows steroid free kidney transplantation. Transplant. Proc. (2000) 33:3176–3177.
   Google Scholar
• MARIAT C, AFIANI A, ALAMARTINE E et al.: A pilot study comparing Basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients. Transplant. Proc. (2001) 33:3192–3193.
   PubMed Web of Science ®Google Scholar
• OFFNER G, BROYER M, LOIRAT C et al.: Multicenter study of the safety and tolerability of Basiliximab (simulect) in Be novo pediatric renal transplantation. Transplantation (2000) 69:S259.
   Google Scholar
• KOHN RA, SHERBOTIE JR, GRIMM PC et al: Basiliximab (Basiliximab) dramatically reduces acute rejection after pediatric kidney transplantation. Transplantation (2000) 69:S260–S261.
   Google Scholar
• FALKENSTEIN KP, CASAS AT, FLYNN LM et al.: A comparison of humanized monoclonal antibody (Basilixmab) induction therapy versus standard immunosuppression in pediatric liver transplant recipients. Transplantation (2000) 69:S170–S171.
   Google Scholar
• KODE RK, KUMAR AMS, PANKEWYCZ 0 et al.: Basiliximab induction is safer and more effective than OKT3 in kidney recipients older than 60 years. Transplantation (2000) 69:S157.
   Google Scholar
• ELKHAMMAS EA, HENRY ML, DEMIRAG A et al.: Basiliximab versus OKT3 in primary simultaneous pancreas-kidney transplant recipients. Transplantation (2000) 69:S407.
   Google Scholar
• HESSE UJ, TROISI R, JACOBS Bet al.: Asingle center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Clin. Transplant. (2000) 14:340–400.
   Google Scholar
• BOGGI U, VISTOLI A, COPPELLI A et al: Use of Basiliximab in conjunction with either neural/MMF/steroid or prograf/MMF/steroids in simultaneous pancreas kidney transplantation. Transplant. Proc. (2001) 33:3201–3202.
   PubMed Web of Science ®Google Scholar
• ELKHAMMAS EA, HENRY ML, DEMIRAG A et al.: Basiliximab versus OKT3 in liver transplantation. Transplantation (2000) 69:S167.
   Google Scholar
• SAUER IM, LANGREHR JM, PASCHER A et al: Tacrolimus and corticosteroids versus tacrolimus, corticosteroids and Basiliximab for control of acute rejection in de novo liver transplant recipients: A matched pair analysis. Transplantation (2000) 69:S168.
   Google Scholar
• JOHNSON SR, WHITING JF, KELLY B et al.: Basiliximab versus OKT3 following orthotopic liver transplantation (OLTX). Transplantation (2000) 69:S167.
   Google Scholar
• LORBER MI, FASTENAU J, WILSON D et al.: A prospective economic evaluation of Basiliximab (Basiliximab) therapy following renal transplantation. Clin. Transplantation (2000) 14:479–485.
   PubMed Web of Science ®Google Scholar
• KEOWN PA, BALSHAW R, KRUEGER H et al.: Economic analysis of Basiliximab in renal transplantation. Transplantation (2001) 71:1573–1579.
   PubMed Web of Science ®Google Scholar
• POLSKY D, VVEINFURT KP, KAPLAN B et al.: An economic and quality of life assessment of Basiliximab versus anthithymocyte globulin immunoprophylaxis in renal transplantation. Nephrol. Dial. Transplant. (2001) 16:1028–1033.
   PubMed Web of Science ®Google Scholar